SLC38A9, a member of the solute carrier family, is a protein that is intricately involved in amino acid transport and mTOR signaling. The activity of this protein can be influenced by several chemical activators through various signaling pathways. Compounds that elevate intracellular levels of cyclic adenosine monophosphate (cAMP) can enhance the functional activity of SLC38A9. This elevation can be achieved through direct stimulation of adenylyl cyclase or by inhibiting the degradation of cAMP via phosphodiesterase inhibition. Increased cAMP levels result in a cascade of events that may lead to the activation of protein kinase A (PKA) and subsequent phosphorylation of downstream targets, which could include pathways that indirectly influence SLC38A9 activity. Additionally, certain phosphodiesterase inhibitors specifically elevate cyclic guanosine monophosphate (cGMP) levels, which can also modulate pathways that intersect with cAMP signaling, indirectly supporting the activation of SLC38A9.
Beyond the cAMP/cGMP axis, other molecular entities function through distinct mechanisms to activate SLC38A9. Compounds that inhibit tyrosine kinases or phosphoinositide 3-kinases (PI3K) can alter downstream signaling pathways, potentially leading to the activation of SLC38A9. For example, by modulating the AKT pathway, a PI3K inhibitor may indirectly activate SLC38A9 as part of the cellular response to changes in nutrient availability or growth signals. Similarly, inhibitors of protein kinase C may alter cellular signaling in a manner that promotes SLC38A9 activity. Furthermore, certain polyphenols activate sirtuin pathways, which are known to influence the mammalian target of rapamycin (mTOR) signaling, a key regulator of amino acid sensing and transport.
VEJA TAMBÉM
Items 1 to 10 of 12 total
Mostrar:
| Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Estimula diretamente a adenilil ciclase, aumentando os níveis intracelulares de AMPc, aumentando assim potencialmente a atividade do SLC38A9. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Inibidor não seletivo da fosfodiesterase, evita a degradação do AMPc, apoiando potencialmente a função do SLC38A9. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Inibidor seletivo da fosfodiesterase 4, aumentando as concentrações de AMPc, o que pode aumentar a atividade do SLC38A9. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
agonista β-adrenérgico que aumenta os níveis de AMPc, possivelmente facilitando a atividade do SLC38A9. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Inibe a fosfodiesterase 5, aumentando os níveis de GMPc, o que pode afetar indiretamente as vias do AMPc, favorecendo a atividade do SLC38A9. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Inibe a fosfodiesterase 1, elevando os níveis de cAMP e cGMP, contribuindo potencialmente para a ativação do SLC38A9. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Inibidor da fosfodiesterase 3, aumentando os níveis de AMPc, o que poderia aumentar a atividade funcional do SLC38A9. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $26.00 $50.00 $99.00 $150.00 $1887.00 | 40 | |
É conhecido por inibir a proteína quinase C, o que pode levar a alterações nas vias de sinalização que activam o SLC38A9. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Inibidor da tirosina quinase, pode alterar a sinalização a jusante, promovendo potencialmente a atividade do SLC38A9. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
O inibidor da PI3K modula a via da AKT a jusante, o que pode resultar na ativação funcional do SLC38A9. | ||||||